EWTX
Edgewise Therapeutics Inc
41.40$
+2.3%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -100.0% | – | – | – | -100.0% | – | – | – | – | – | – | |
| – | – | – | – | – | -35.4% | +25.5% | +21.9% | +62.8% | +21.3% | +7.1% | -44.2% | +162.0% | +81.3% | +2.5% | +19.0% | -1.5% | +1.7% | +328.8% | -53.8% | -47.7% | +2.3% | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -130.5% | – | – | – | -152.3% | – | – | – | – | – | – | |
| – | +22.6% | -11.0% | +58.7% | +4.3% | +46.7% | +25.7% | -8.0% | +22.4% | +11.5% | +12.0% | +19.6% | +19.6% | -1.6% | +21.6% | +16.4% | +0.0% | +10.8% | +5.0% | +12.9% | +1.1% | -8.7% | +11.7% | +16.3% | -2.2% | +11.5% | – | |
| – | +13.2% | +27.4% | +197.5% | +24.2% | +73.6% | +23.0% | +16.8% | -0.9% | +10.5% | +6.8% | +25.2% | +6.6% | -0.8% | -2.0% | +9.0% | +14.3% | +5.2% | +10.5% | +11.7% | +0.3% | -1.6% | +3.6% | +32.1% | -7.4% | +25.6% | – | |
| – | +21.8% | -7.9% | +74.1% | +8.1% | +52.5% | +25.0% | -1.9% | +15.6% | +11.2% | +10.7% | +20.9% | +16.4% | -1.4% | +16.2% | +15.0% | +2.6% | +9.7% | +6.1% | +12.6% | +0.9% | -7.3% | +10.0% | +19.5% | -4.4% | +15.7% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -95.2% | -66.7% | +100.0% | +2,000.0% | +154.8% | +18.7% | -0.8% | +31.7% | +155.4% | +80.2% | +248.7% | +16.6% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | -100.4% | – | – | – | – | – | -246.6% | – | -86.6% | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.